#T1DM
I think it is also worth emphasizing that yes, the *prevalence* of T1DM is almost certainly higher than it ever was in the past, for the simple reason that better medical care means that people with T1DM live far longer than they used to. MAHA would rather people be dead than have a chronic disease.
November 14, 2026 at 7:16 PM
Since one scientific theory is that T1DM is an autoimmune condition triggered by a viral infection, then getting vaccinated to the hilt would likely reduce your chances of developing diabetes. But, you know, facts - who need em?
November 14, 2026 at 1:59 PM
(2024)

Epidemiologisissa tutkimuksissa ja meta-analyyseissä on raportoitu tyypin 1 diabeteksen ilmaantuvuuden kasvusta koronapandemian aikana sekä koronatartunnan ja uuden tyypin 1 diabeteksen puhkeamisriskin välisestä yhteydestä.

www.nature.com/articles/s41…

#koronafi
The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus - Nature Reviews Endocrinology
Many studies identified an increase in the incidence of type 1 diabetes mellitus (T1DM) during the COVID-19 pandemic, but other reports do not support this association. This Review addresses the issue of the involvement of SARS-CoV-2 infection in the development of T1DM using evidence from epidemiological, clinical and experimental studies.
www.nature.com
November 17, 2026 at 4:42 PM
Screening for early-stage type 1 diabetes mellitus
Eisenbarth, G. S. Type I diabetes mellitus. N. Engl. J. Med. 314, 1360–1368 (1986). Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964–1974 (2015). This scientific statement introduces the staging of early-stage T1DM based on IAbs and glycaemic status, which underpins current screening and intervention strategies. American Diabetes Association Professional Practice Committee for Diabetes 2. Diagnosis and Classification of Diabetes: standards of care in diabetes — 2026. Diabetes Care 49, S27–S49 (2026). Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603–613 (2019). This landmark trial shows that an immunotherapy, teplizumab, can delay the onset of clinical T1DM in individuals with stage 2 disease. Ziegler, A.-G. The countdown to type 1 diabetes: when, how and why does the clock start? Diabetologia 66, 1169–1178 (2023). Riley, W. J., Atkinson, M. A., Schatz, D. A. & Maclaren, N. K. Comparison of islet autoantibodies in ‘pre-diabetes’ and recommendations for screening. J. Autoimmun. 3, 47–51 (1990). McQueen, R. B. et al. Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado...
www.nature.com
November 11, 2026 at 4:21 PM
JMIR Formative Res: Mobile App for Assisting Patients With Type 1 Diabetes in Insulin Dose Adjustment: Development and #usability Study #Type1Diabetes #DiabetesManagement #InsulinTherapy #MobileHealth #HealthTech
Mobile App for Assisting Patients With Type 1 Diabetes in Insulin Dose Adjustment: Development and #usability Study
Background: In resource-limited countries, most patients with type 1 diabetes (T1DM) use basal-bolus insulin therapy. Optimal dosing requires matching insulin to carbohydrate intake, premeal blood glucose levels, and physical activity—a complex process prone to error, particularly for patients with limited health literacy. Objective: This study aimed to develop and pilot-test a new mobile app designed to adjust bolus insulin doses based on the carbohydrate content of the meal, premeal blood glucose, and physical activity, tailored specifically for Iraqi patients with T1DM. Methods: To guide the app’s development, a literature search was conducted to identify key features in mobile apps for improving glycemic control in patients with T1DM. Evidence highlighted bolus insulin calculation, blood glucose tracking, and patient education as the most impactful features; consequently, these 3 functionalities were selected as the core components of the app. The scientific content of the app was based mainly on the latest American Diabetes Association guidelines and reviewed by 8 experts to ensure accuracy. After initial app prototype development, a cross-sectional pilot #feasibility study was conducted at the Diabetes and Endocrine Center in Basrah, Iraq. A purposive sample of 10 health care professionals (5 endocrinologists, 2 dietitians, 2 clinical pharmacists, and 1 diabetes educator) and 10 patients with T1DM (aged ≥15 y) was recruited. The app was installed on participants’ smartphones, and standardized instructions on its functions and usage were provided. After a 10- to 14-day trial period, participants evaluated the #usability, satisfaction, and perceived benefits of the app using newly developed and validated 3-point Likert scale questionnaires (one specific to patients and the other to health care professionals), alongside an optional open-ended question for qualitative feedback. Results: Positive feedback was reported across both groups. A favorable #usability rating was expressed by 80% of experts and 90% of patients. Regarding app benefits, 90% of experts and nearly all patients considered it effective for adjusting insulin doses, improving treatment adherence, and reducing hypoglycemia. At least 70% of experts noted provider benefits (reduced workload and improved monitoring). All participants were satisfied and would recommend the app. Conclusions: The new app tested in this study demonstrated promising acceptability and #usability among patients with T1DM and relevant health care professionals. However, given the small sample size, these findings should be interpreted as preliminary #feasibility evidence. A larger, adequately powered clinical trial is warranted to confirm these results and evaluate the app’s clinical impact on glycemic outcomes. Trial Registration: PROSPERO CRD420251185239; https://www.crd.york.ac.uk/PROSPERO/view/1185239
dlvr.it
November 6, 2026 at 9:41 PM
New Chinese study of 401 kids with T1DM shows striking age differences: younger kids have worse islet function (lower C-peptide), older ones face more thyroid antibodies & vitamin D deficiency.

Age-specific care is key.

link.springer.com/article/10.1...

#T1DM #PediatricDiabetes
October 30, 2026 at 8:26 AM
ICYMI: New content online: Gut microbiome development could predict T1DM risk
Gut microbiome development could predict T1DM risk
Nature Reviews Endocrinology, Published online: 21 October 2026; doi:10.1038/s41574-026-01320-2Gut microbiome development could predict T1DM risk
go.nature.com
October 23, 2026 at 2:38 PM
New content online: Gut microbiome development could predict T1DM risk
Gut microbiome development could predict T1DM risk
Nature Reviews Endocrinology, Published online: 21 October 2026; doi:10.1038/s41574-026-01320-2Gut microbiome development could predict T1DM risk
go.nature.com
October 21, 2026 at 2:38 PM
Perhaps the Dem candidate tripping at the finish line with a bad case of the flu/exhaustion/+T1DM complications has costs in polling!

Winning Texas is a physical ordeal.
October 14, 2026 at 3:48 PM
I have always liked Brett Michaels. Having T1dm myself- have to support
October 10, 2026 at 9:30 PM
Impact of diabetes mellitus on the menopausal experience: A scoping review - Black - 2026 - Diabetic Medicine - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/...

Thank you to everyone who made this possible 💙
<em>Diabetic Medicine</em> | Diabetes UK Journal | Wiley Online Library
Aims To identify, appraise and synthesise the current evidence relating to symptoms, experiences, management and impact of menopause on QoL among women with type 1 diabetes (T1DM) or type 2 diabetes...
onlinelibrary.wiley.com
October 7, 2026 at 10:35 AM
Can gingiva-derived MSCs (GMSCs) help preserve β-cell function in #Type1Diabetes (#T1DM)? A phase 1 trial links GMSC therapy to improved residual β-cell function, potentially through CD8+ T-cell exhaustion.

#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #BetaCellFunction
October 3, 2026 at 12:30 PM
Unrelated but there is an incredibly easy cohort study just begging to be done: Admission rate for DKA for kids with T1DM seen by MHS peds endos vs Tricare outside providers vs regular care.
September 28, 2026 at 2:40 AM
mydiabetes*myway offer courses that you can sign-up to at any time and complete when it suits you.

Our courses are free and open to everyone - even if you do not have diabetes. They cover T1DM & T2DM management and devices that you may now be using.

elearning.mydiabetesmyway.scot.nhs.uk/courses/
September 25, 2026 at 3:09 PM
New JMIR Diabetes: SMARTCLOTH-Odyssey for Nutrition Education in Type 1 #diabetes: Development and Acceptability Study of a Gamified Web-Based Platform for #diabetes Nurse Educators Using a Human-Centered Design Approach
SMARTCLOTH-Odyssey for Nutrition Education in Type 1 #diabetes: Development and Acceptability Study of a Gamified Web-Based Platform for #diabetes Nurse Educators Using a Human-Centered Design Approach
Background: The onset of type 1 #diabetes mellitus (T1DM) in adolescence represents a challenge for patients, families, and health care professionals. #diabetes nurse educators identify a lack of adolescent-friendly educational resources, especially in nutrition education. Digital technology offers an opportunity to develop innovative tools to address these needs from a user-centered approach. Objective: We aimed to design and evaluate the acceptability of the SMARTCLOTH-Odyssey platform, an interactive web tool designed to support #diabetes nurse educators in delivering nutrition education based on carbohydrate counting to adolescents with recent T1DM, evaluated from the perspective of nurse educators. Methods: A mixed study was carried out in three phases: (1) qualitative analysis through two focus groups with nurse educators in the Andalusian Community to identify barriers and needs; (2) development of the digital tool following a human-centered design methodology, incorporating narrative and gamified elements; and (3) quantitative evaluation of acceptability through an ad hoc questionnaire applied to 40 professionals who tested the platform. Results: Participants highlighted the lack of homogeneous and adapted debut materials, and the need for emotionally sensitive and visually appealing tools. SMARTCLOTH-Odyssey was rated positively in terms of usefulness, clarity, and clinical applicability. A total of 97.5% (39/40) felt it could facilitate nutrition education, and 90% (36/40) said they would use it in their practice. The platform was perceived as intuitive, innovative, and adapted to the characteristics of the adolescent patient. Conclusions: SMARTCLOTH-Odyssey constitutes a viable and well-valued proposal by nurse educators. It has the potential to improve nutrition education from the diagnosis of T1DM. Its participatory development reinforces its applicability and sustainability in real clinical contexts.
dlvr.it
September 25, 2026 at 3:15 PM
In October: Reviews on lupus nephritis management; metabolic changes in autoimmune disease; the potassium switch; and epigenetics in kidney development, plus Commentaries on kidney protection in T1DM; gaps in care for young adults; nephrology in Taiwan; and palliative care go.nature.com/4dpPIom
September 20, 2026 at 7:05 AM
Here, Francisca L. Henriques, Irina Buckle & Josephine M. Forbes review strategies for type 1 diabetes mellitus prevention (£) go.nature.com/4gT9Stf #EndoSky #MedSky
September 14, 2026 at 3:52 PM
I totally forgot there was a month where the social media algorithms absolutely thought they had clocked that I had type 1 diabetes. Constant T1DM content. It was so weird.
September 10, 2026 at 7:46 AM
A person with T1DM does not acquire T2DM. At least my opinions are informed, which is more than I can say for yours.
September 1, 2026 at 3:59 PM
I didn't say they could. I said T1DM people are born with diabetes. T2DM can acquire it, sometimes through excessive weight gain. Learn to read.
September 1, 2026 at 4:03 PM
One is born with T1DM and often acquires T2DM. Losing weight can cure T2DM in some people. Like your opinion makes any difference.
September 1, 2026 at 3:18 PM
It makes a little more sense in T1DM. It doesn’t have the same pathology as T2DM, which doesn’t spring from an inability to produce insulin but is instead starts with a defect in insulin uptake by cells. Making more insulin doesn’t fix that.
September 1, 2026 at 2:30 PM